This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Metastasis | |
|---|---|
| Name | Metastasis |
| Field | Oncology |
| Synonyms | Secondary cancer |
Metastasis
Metastasis is the process by which malignant cells spread from a primary neoplasm to establish secondary tumors at distant sites. It underlies the lethality of many cancers and intersects with clinical practice in oncology, surgical oncology, radiology, and pathology. Historical advances from researchers and institutions across Europe, North America, and Asia have shaped contemporary understanding and management strategies.
Metastasis arises when cells from a primary tumor acquire capacities that allow invasion, intravasation, survival in circulation, extravasation, and colonization of distant tissues. Key historical figures and institutions that contributed to this concept include Rudolf Virchow, Theodor Boveri, William Osler, John Hunter, Royal College of Surgeons, and Memorial Sloan Kettering Cancer Center. The modern conceptual framework draws on discoveries reported in journals and conferences associated with American Society of Clinical Oncology, European Society for Medical Oncology, National Cancer Institute, World Health Organization, and academic centers like Johns Hopkins University, Massachusetts General Hospital, University of Cambridge, University of Oxford, Karolinska Institutet, and MD Anderson Cancer Center.
Molecular and cellular mechanisms involve genetic and epigenetic alterations, epithelial-to-mesenchymal transition, interaction with stromal components, and exploitation of vascular routes. Seminal molecular pathways were elucidated by labs at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, Max Planck Society, Broad Institute, Dana-Farber Cancer Institute, and researchers such as Harold Varmus, Robert Weinberg, Bert Vogelstein, James Allison, and Tasuku Honjo. Processes like protease secretion, integrin signaling, chemokine receptor engagement, and pre-metastatic niche formation have been studied in contexts linked to Nature, Science, Cell (journal), and conferences hosted by American Association for Cancer Research. Animal models and technologies from SALK Institute, Scripps Research, Fred Hutchinson Cancer Center, Institut Pasteur, ETH Zurich, University of Tokyo, and Shanghai Jiao Tong University have enabled dissection of invasion, intravasation, and immune evasion.
Certain malignancies preferentially seed specific organs, reflecting tumor–host interactions, circulatory patterns, and tropism. Classic examples and centers reporting patterns include studies from Royal Marsden Hospital, Gustave Roussy, Memorial Sloan Kettering Cancer Center, Mayo Clinic, Cleveland Clinic, UCSF Medical Center, and cancer registries such as Surveillance, Epidemiology, and End Results Program and Cancer Research UK. Patterns described historically in literature from Harvard Medical School, Yale School of Medicine, Cornell University, University of California, Los Angeles, Stanford University, University of Pennsylvania, and Vanderbilt University include liver metastases from colorectal primaries, lung metastases from sarcomas, bone metastases from prostate and breast cancers, and brain metastases from melanoma and lung carcinoma.
Diagnosis integrates clinical assessment, imaging, and histopathology using modalities developed and refined by institutions and companies linked to World Health Organization, European Organisation for Research and Treatment of Cancer, Radiological Society of North America, American College of Radiology, Siemens Healthineers, GE Healthcare, and centers like Mount Sinai Hospital and Royal Free Hospital. Imaging approaches include CT, MRI, PET, and ultrasound, with molecular profiling and liquid biopsy techniques emerging from collaborations involving Illumina, Foundation Medicine, Guardant Health, Broad Institute, and university centers such as Johns Hopkins University and University of Chicago. Pathologic confirmation often references protocols and classifications from American Society of Clinical Pathology, College of American Pathologists, International Agency for Research on Cancer, and textbooks edited at Oxford University Press and Cambridge University Press.
Management strategies combine local and systemic therapies coordinated by multidisciplinary teams in hospitals like MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, and Peter MacCallum Cancer Centre. Surgical resection, metastasectomy, stereotactic radiosurgery developed at institutions such as Karolinska Institutet and UCLA Health, systemic chemotherapy, targeted therapy pioneered by companies like Roche, Novartis, Pfizer, and immune checkpoint inhibitors advanced by research at University of Texas MD Anderson Cancer Center and University of Pennsylvania all contribute. Palliative care and supportive oncology programs from Hospice UK, American Cancer Society, St. Jude Children’s Research Hospital, and M.D. Anderson Cancer Center inform symptom management.
Prognosis depends on tumor biology, metastatic burden, and access to care; epidemiologic data derive from registries and agencies including Surveillance, Epidemiology, and End Results Program, International Agency for Research on Cancer, Cancer Research UK, Centers for Disease Control and Prevention, Public Health England, and national cancer institutes across Canada, Australia, Germany, France, Japan, and China. Landmark epidemiologists and statisticians associated with Johns Hopkins Bloomberg School of Public Health, Harvard T.H. Chan School of Public Health, London School of Hygiene & Tropical Medicine, and Karolinska Institutet have quantified incidence, survival, and trends, informing guidelines from National Comprehensive Cancer Network and European Society for Medical Oncology.
Cutting-edge research integrates genomics, immunotherapy, liquid biopsy, and targeted delivery systems advanced by consortia and institutions like Broad Institute, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, National Institutes of Health, Bill & Melinda Gates Foundation, Cancer Research UK, Chan Zuckerberg Initiative, and biotech firms including Moderna, Gilead Sciences, Amgen, Bristol-Myers Squibb. Clinical trials coordinated by cooperative groups such as EORTC, NCI Cooperative Groups, SWOG, and Alliance for Clinical Trials in Oncology explore CAR T-cell therapies, bispecific antibodies, metastasis-directed radiotherapy, and metastasis-preventive strategies developed with input from FDA, EMA, and academic translational units at Stanford Cancer Institute, Yale Cancer Center, Dana-Farber Cancer Institute, and UCSF Helen Diller Family Comprehensive Cancer Center.